Showing results (51-60 of 154) with videos related to

Sort By:
Pageof 16
Blood Reviews|November 11, 2017
Using prognostic models in CLL to personalize approach to clinical care: Are we there yet?Alain Mina, Jose Sandoval Sus, Elsa Sleiman, et al.
Cancer Nursing|November 11, 2016
Adapting an Evidence-Based Intervention to Address Targeted Therapy-Related Fatigue in Chronic Myeloid Leukemia PatientsHanneke Poort, Cathy D Meade, Hans Knoop, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 14, 2017
Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and ManagementJorge E Cortes, Carlos A Jimenez, Michael J Mauro, et al.
Blood Advances|February 12, 2020
Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemiaOnyee Chan, Chetasi Talati, Leidy Isenalumhe, et al.
Blood|September 25, 2003
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemiaKathleen Cathcart, Javier Pinilla-Ibarz, Tatyana Korontsvit, et al.
Blood|May 3, 2002
Vaccination with CD20 peptides induces a biologically active, specific immune response in miceWendy K Roberts, Philip O Livingston, David B Agus, et al.
Annals of Hematology|February 13, 2023
Risks and outcomes of hospitalizations in patients with chronic lymphocytic leukemia admitted with immune thrombocytopenia: an analysis of the National Inpatient Sample DatabaseMohammad Ammad Ud Din, Amir Mahmud, Mariam Mostafa, et al.
Cancer|March 24, 2010
Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intoleranceHagop Kantarjian, Phillipp le Coutre, Jorge Cortes, et al.
Leukemia Research|March 15, 2006
Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 moleculesMarta Gomez-Nunez, Javier Pinilla-Ibarz, Tao Dao, et al.
Annals of Hematology|March 21, 2018
Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE studyDong-Wook Kim, Susanne Saussele, Loretta A Williams, et al.
Pageof 16